Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Mar 17, 2023 5:37pm
348 Views
Post# 35346130

Countdown

CountdownMidatech's General Meeting takes place on March 24, 2023, as detailed on page 24 of Midatech's Notice of General Meeting. That's on a Friday, one week from today.

On Monday, March 27, Midatech will be rolled back (20 to 1), the company becomes Biodexa, and the certain terms of the recent financing and prepaid warrants become official.

Bioasis has claimed to have enough money until the end of March, likely meaning that Bioasis will be in default of its scheduled payment to Lind on or after April 1, 2023.

The question is whether Biodexa will make the final tranche of their loan to Bioasis sometime between Monday, March 27 and Saturday, April 1, allowing Bioasis to avoid default..

As I have posted, after the General Meeting, Midatech (Biodexa) will have a new structure, essentially new ownership, and the company can then spend it financing proceeds as it sees fit, including buying Bioasis without further Biodexa shareholder approval.

Because Bioasis shareholders have already approved it, it wouldn't surprise me if Bioasis announces next week, or by Monday, April 3, or shortly after, that Bioasis is being, or has been, sold to Biodexa.

If the ratio of the percentage of Biodexa ownership by former Midatech to Bioasis shareholders stands, then Bioasis shareholders can expect to own as little as about 3% of Biodexa.

I suspect that the recent Midatech financing was not done based on Midatech's current IP assets and their prospects. I suspect it was done to get the Bioasis deal done, to get xB3, that Midatech/Biodexa needs Bioasis to justify the financing and prepaid warrant investment by the placees.

I don't know if all or any of this will happen, but based on previous Bioasis guidance, there is a short countdown to a Lind default. If the things I've described happen then at least you can say you suspected it, and that it was publicly discussed here on SH before the possible secret intentions and machinations of Rathjen bore their awful results.

jd

<< Previous
Bullboard Posts
Next >>